arrow
C

Christopher J. Sayed

University of North Carolina at Chapel Hill School of Medicine
H指数:21
被引数:2,540

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

Bimekizumab在治疗中度至重度化脓性汗腺炎的患者中,显示出良好的安全性和高水平的疗效,治疗时间长达2年:来自两项III期随机对照试验及其开放标签扩展研究的合并结果

2025-11-150
PRE
Vilobelimab to improve clinical outcomes in moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: results of the SHINE double-blind placebo-controlled randomized trial

Vilobelimab通过在引流隧道上的附加作用改善中重度化脓性汗腺炎的临床结局:SHINE双盲、安慰剂对照随机试验结果

2025-11-011
OAAI
Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials

Bimekizumab治疗化脓性汗腺炎患者的疼痛结局:来自BE HEARD I&II III期随机临床试验合并48周结果

2025-10-170
OA
Genomic loci and molecular genetic mechanisms for hidradenitis suppurativa

HS的基因组位点与分子遗传机制

2025-09-012
OAAI
Standardized Protocols for Clinical and Histopathological Characterization of Hidradenitis Suppurativa Tissue Specimens
2025-01-010
PRE
North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations
2024-12-011
PRE